Dividends & Buybacks ·
POMDOCTOR shareholders approve ten-for-one share consolidation and ADR termination for Nasdaq direct listing
POMPOMDOCTOR Ltd
On September 30, 2026, POMDOCTOR Limited shareholders approved the termination of its American Depositary Receipt program and a ten-for-one share consolidation. The ADR termination and direct listing on Nasdaq will occur simultaneously with the consolidation, which increases par value from US$0.0001 to US$0.001 per share. The company also amended its authorized share capital from 500 million to 50 million shares while maintaining a total par value of US$50,000. Fractional shares resulting from the consolidation will be rounded up to the nearest whole number. POMDOCTOR Limited operates in the healthcare technology industry, providing digital health solutions.